HeartSciences Inc. (HSCS)
| Market Cap | 13.58M +52.4% |
| Revenue (ttm) | 4,519 -27.7% |
| Net Income | -10.26M |
| EPS | -3.19 |
| Shares Out | 4.80M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 76,632 |
| Open | 2.750 |
| Previous Close | 2.670 |
| Day's Range | 2.750 - 3.071 |
| 52-Week Range | 1.630 - 5.250 |
| Beta | 1.81 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Dec 14, 2026 |
About HSCS
HeartSciences Inc., a medical technology company, focuses on advancing electrocardiography (ECG) through the integration of artificial intelligence. It develops artificial intelligence-enhanced electrocardiography (AI-ECG) solutions, an algorithm to detect impaired cardiac relaxation or cardiac dysfunction; MyoVista wavECG device, a resting 12-lead ECG that provides diagnostic information related to cardiac dysfunction, as well as conventional ECG information in the same test; and MyoVista Insights, a cloud-native vendor- and device-agnostic EC... [Read more]
Financial Performance
In fiscal year 2026, HeartSciences's revenue was $4,319, a decrease of -0.71% compared to the previous year's $4,350. Losses were -$9.14 million, 4.30% more than in 2025.
Financial StatementsNews
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on November 6, 2026, providing details for shareholder voting and corporate governance matters.
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on November 6, 2026, providing details for shareholder voting and corporate governance matters.
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on November 5, 2026, providing details for shareholder voting and corporate governance matters.
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on November 4, 2026, providing details for shareholder voting and corporate governance matters.
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on November 3, 2026, providing details for shareholder voting and corporate governance matters.
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on November 2, 2026, providing details for shareholder voting and corporate governance matters.
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on October 30, 2026, providing details for shareholder voting and corporate governance matters.
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on October 29, 2026, providing details for shareholder voting and corporate governance matters.
HeartSciences announces 15-MW facility in Nebraska participates in SPP
Fortitude Mining announced that its 15-megawatt, MW, facility in Aurora, Nebraska, is participating in the Southwest Power Pool, SPP, wholesale electricity markets through Dispatchable Demand Response...
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on October 28, 2026, providing details for shareholder voting and corporate governance matters.
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on October 27, 2026, providing details for shareholder voting and corporate governance matters.
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on October 26, 2026, providing details for shareholder voting and corporate governance matters.
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on October 26, 2026, providing details for shareholder voting and corporate governance matters.
HeartSciences sets November 19 vote on Fortitude Mining combination
HeartSciences (HSCS) announced that it has filed its definitive proxy statement with the SEC in connection with its previously announced proposed business combination with Fortitude Mining Holdings, a...
HeartSciences Files Definitive Proxy Statement for Proposed Business Combination with Fortitude Mining
Definitive proxy statement filed with the SEC, marking an important milestone toward completion of the proposed transaction HeartSciences Board of Directors unanimously recommends shareholders vote FO...
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on October 21, 2026, providing details for shareholder voting and corporate governance matters.
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on October 19, 2026, providing details for shareholder voting and corporate governance matters.
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on October 19, 2026, providing details for shareholder voting and corporate governance matters.
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on October 19, 2026, providing details for shareholder voting and corporate governance matters.
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on October 15, 2026, providing details for shareholder voting and corporate governance matters.
HeartSciences gets FDA clearance for MyoVista wavECG device
HeartSciences (HSCS) announced that the FDA has granted 510 clearance for its MyoVista wavECG device as a 12-lead resting electrocardiograph. The clearance covers the acquisition and interpretation of...
HeartSciences Receives FDA 510(k) Clearance for its MyoVista® wavECGTM Device
Southlake, TX, Oct. 06, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company focused on advancing e...
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on October 6, 2026, providing details for shareholder voting and corporate governance matters.
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on October 6, 2026, providing details for shareholder voting and corporate governance matters.
HeartSciences Proxy statement: Proxy filing
HeartSciences filed a proxy statement on October 6, 2026, providing details for shareholder voting and corporate governance matters.